Reply to Collins et al. and to Singh [3]

Lionel A. Mandell; Richard G. Wunderink; Antonio Anzueto; John G. Bartlett; G. Douglas Campbell; Nathan C. Dean; Scott F. Dowell; Thomas M. File; Daniel M. Musher; Michael S. Niederman; Antonio Torres; Cynthia G. Whitney; Martin Cormican

doi:10.1086/518704

Reply to Collins et al. and to Singh [3]

Lionel A. Mandell, Richard G. Wunderink, Antonio Anzueto, John G. Bartlett, G. Douglas Campbell, Nathan C. Dean, Scott F. Dowell, Thomas M. File, Daniel M. Musher, Michael S. Niederman, Antonio Torres, Cynthia G. Whitney, Martin Cormican

Division of Pulmonary Diseases

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	134-135
Number of pages	2
Journal	Clinical Infectious Diseases
Volume	45
Issue number	1
DOIs	https://doi.org/10.1086/518704
State	Published - Jul 1 2007

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1086/518704

Cite this

@article{7242ec379181446fad322d75895719e1,

title = "Reply to Collins et al. and to Singh [3]",

author = "Mandell, {Lionel A.} and Wunderink, {Richard G.} and Antonio Anzueto and Bartlett, {John G.} and Campbell, {G. Douglas} and Dean, {Nathan C.} and Dowell, {Scott F.} and File, {Thomas M.} and Musher, {Daniel M.} and Niederman, {Michael S.} and Antonio Torres and Whitney, {Cynthia G.} and Martin Cormican",

note = "Funding Information: entis, Targanta, and Wyeth; has provided research support to Bayer, Novartis, Ortho-McNeil, Os-cient, and Pfizer; and has been a member of the Speakers{\textquoteright} Bureaus of Bayer, Ortho-McNeil, Os-cient, Pfizer, Sanofi-Aventis, and Abbott. R.G.W. has received research funding from Chiron, Eli Lilly, Pfizer, and Wyeth; has served on the Clinical Evaluation Committee for Johnson and Johnson; has served as a clinical trial participant in studies initiated by Takeda, Biosite, Inverness Medical Intervention, Johnson and Johnson, and Altana; and served as consultant to the Oklahoma Foundation for Medical Quality and the Centers for Medicare and Medicaid Services. J.G.B. serves on the advisory board of Johnson and Johnson. T.M.F. has received research funding from Binax, Ortho-McNeil, Oscient, Pfizer, and Sanofi-Aventis; has served as a consultant to Bayer, GlaxoSmithKline, Merck, Ortho-McNeil, Oscient, Pfizer, Sanofi-Av-entis, Schering-Plough, and Wyeth; and has served on the Speakers{\textquoteright} Bureaus of Abbott, Glaxo-SmithKline, Merck, Ortho McNeil, Oscient, Pfizer, Sanofi-Aventis, Schering Plough, and Wyeth. N.C.D. has received research support from Altana and Sanofi-Aventis, has served on the Advisory Boards of Sanofi-Aventis and Astra Zeneca, and has served on the Speakers{\textquoteright} Bureaus of Pfizer, Sch-ering Plough, Sanofi-Aventis, and Merck. A.A. has served on the Speakers{\textquoteright} Bureaus of Altana, Bayer Pharma, Boehringer-Ingelheim, Chiron, Elan, GlaxoSmithKline, Ortho-McNeil, Pfizer, and San-ofi-Aventis; has served as a consultant for and has been a member of the Advisory Boards of Altana, Bayer Pharma, Boehringer-Ingelheim, Chiron, Elan, GlaxoSmithKline, Ortho-McNeil, Pfizer, and Sanofi-Aventis; and has received research funding from Bard, Bayer Pharma, Boehringer-Ingelheim, GlaxoSmithKline, and Lilly. M.S.N. serves on the Speakers{\textquoteright} Bureaus of and as a consultant to Astra Zeneca, Aventis, Elan, Merck, Ortho-McNeil, Pfizer, Schering-Plough, and Wyeth. All other authors: no conflicts.",

year = "2007",

month = jul,

day = "1",

doi = "10.1086/518704",

language = "English (US)",

volume = "45",

pages = "134--135",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Reply to Collins et al. and to Singh [3]

AU - Mandell, Lionel A.

AU - Wunderink, Richard G.

AU - Anzueto, Antonio

AU - Bartlett, John G.

AU - Campbell, G. Douglas

AU - Dean, Nathan C.

AU - Dowell, Scott F.

AU - File, Thomas M.

AU - Musher, Daniel M.

AU - Niederman, Michael S.

AU - Torres, Antonio

AU - Whitney, Cynthia G.

AU - Cormican, Martin

N1 - Funding Information: entis, Targanta, and Wyeth; has provided research support to Bayer, Novartis, Ortho-McNeil, Os-cient, and Pfizer; and has been a member of the Speakers’ Bureaus of Bayer, Ortho-McNeil, Os-cient, Pfizer, Sanofi-Aventis, and Abbott. R.G.W. has received research funding from Chiron, Eli Lilly, Pfizer, and Wyeth; has served on the Clinical Evaluation Committee for Johnson and Johnson; has served as a clinical trial participant in studies initiated by Takeda, Biosite, Inverness Medical Intervention, Johnson and Johnson, and Altana; and served as consultant to the Oklahoma Foundation for Medical Quality and the Centers for Medicare and Medicaid Services. J.G.B. serves on the advisory board of Johnson and Johnson. T.M.F. has received research funding from Binax, Ortho-McNeil, Oscient, Pfizer, and Sanofi-Aventis; has served as a consultant to Bayer, GlaxoSmithKline, Merck, Ortho-McNeil, Oscient, Pfizer, Sanofi-Av-entis, Schering-Plough, and Wyeth; and has served on the Speakers’ Bureaus of Abbott, Glaxo-SmithKline, Merck, Ortho McNeil, Oscient, Pfizer, Sanofi-Aventis, Schering Plough, and Wyeth. N.C.D. has received research support from Altana and Sanofi-Aventis, has served on the Advisory Boards of Sanofi-Aventis and Astra Zeneca, and has served on the Speakers’ Bureaus of Pfizer, Sch-ering Plough, Sanofi-Aventis, and Merck. A.A. has served on the Speakers’ Bureaus of Altana, Bayer Pharma, Boehringer-Ingelheim, Chiron, Elan, GlaxoSmithKline, Ortho-McNeil, Pfizer, and San-ofi-Aventis; has served as a consultant for and has been a member of the Advisory Boards of Altana, Bayer Pharma, Boehringer-Ingelheim, Chiron, Elan, GlaxoSmithKline, Ortho-McNeil, Pfizer, and Sanofi-Aventis; and has received research funding from Bard, Bayer Pharma, Boehringer-Ingelheim, GlaxoSmithKline, and Lilly. M.S.N. serves on the Speakers’ Bureaus of and as a consultant to Astra Zeneca, Aventis, Elan, Merck, Ortho-McNeil, Pfizer, Schering-Plough, and Wyeth. All other authors: no conflicts.

PY - 2007/7/1

Y1 - 2007/7/1

UR - http://www.scopus.com/inward/record.url?scp=34250816778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250816778&partnerID=8YFLogxK

U2 - 10.1086/518704

DO - 10.1086/518704

M3 - Letter

AN - SCOPUS:34250816778

SN - 1058-4838

VL - 45

SP - 134

EP - 135

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 1

ER -

Reply to Collins et al. and to Singh [3]

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this